ClinicalTrials.gg
Enrolling by invitationNCT06504043Updated Mar 14, 2025

A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants

A Phase 1 interventional study of HST101 in Hypercholesterolemia, Healthy Volunteers and LDL-Cholesterol, sponsored by Hasten Biopharmaceutical Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Hasten Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Planned enrollment
52nd of 53
30 · median 207
Started
2024
with 5 others
Phase 1
12 of 59
2 open now
Primary completion
2025-01
later than 3 of 16 live
Registered
48th of 59
by date
Lead sponsor
2 of 59
Hasten Biopharmaceutical Co., Ltd.

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 52nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2024, is one of 12 in phase 1, reaches primary completion later than 3 of the 16 other live ones, and was the 48th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, single HST101 SC dose cohort study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Chinese Participants with Elevated LDL-C Levels.

Read the detailed description

The planned 30 study participants will be assigned to low- or high-dose 2 cohorts and 15 participants in each cohort will be randomized to either the HST101 group or the matching dose placebo group and will be administered in subsequent or in-parallel manner. Cohort 1: 15 study participants will receive the low dose of HST101 or placebo at a corresponding dose. Cohort 2: additional 15 study participants will receive the high dose of HST101 or placebo at a corresponding dose.

03

Conditions studied

  • Hypercholesterolemia
  • Healthy Volunteers
  • LDL-Cholesterol
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women who are ≥18 and ≤55 years of age with elevated LDL-C Levels;
  • LDL-C ≥ 2.6 mmol/L (100 mg/dL) and ≤ 4.9 mmol/L (190 mg/dL) and TG ≤ 2.83 mmol/L (250 mg/dL) who are not on a lipid-lowering therapy 30 days prior to screening;
  • (BMI) ≥18 and≤28 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Positive blood screen for antibody, Treponema pallidum antibody, or antibody;
  • liver function test abnormalities at screening, such as or ALT > 2 × , total > 1.5 × ULN, or ALP > 2 × ULN based on normal values;
  • CK > 3 × ULN at the screening visit, it can be retested if considered to be related to exercise;
  • History of prescription drug abuse, illicit drug use or alcohol abuse;
  • Use of any prescription drug, herbal and compound decoction, vitamins, minerals, and OTC drugs and nutritional supplements that alter lipid metabolism within 14 days prior to Check-in and planned use of the above drugs throughout the study;
  • Prior treatment with PCSK9 inhibitors, including mAbs, siRNA products, or any Adnectin products;
  • History of allergy to protein-based biologics including, but not limited to, mAbs and vaccine;
  • Less than 30 days or less than 5 half-lives (drug) since the end of participation in another clinical trial (drug or device), whichever is longer;
  • Use of any other biologics within 3 months prior to product administration;
  • Any other significant clinical diseases or psychological diseases that the investigator considers to be inappropriate for participation in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental: cohort low dose HST101

    HST101 single SC administration of 150 mg or placebo;

    Drug: HST101

  • Experimental
    Experimental: cohort high dose HST101

    HST101 single SC administration of 300 mg or placebo.

    Drug: HST101

Interventions

  • DrugHST101

    HST101 is a novel anti-PCSK9 fusion protein

    Also known as: Lerodalcibep

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to assess the safety and tolerability of a single SC dose of HST101 in Chinese healthy adult study participants with elevated LDL-C level(International Standard Unit: mmol/L)

    Safety and tolerability will be assessed by the incidence and severity of treatment emergent adverse events

    Time frame: 57 days

Secondary outcomes

  1. To assess the pharmacokinetic characteristics and dose proportionality relathionship of HST101 following a single SC dose

    The PK parameters include Cmax, Tmax, T1/2, AUC0-t, AUCinf and others if necessary

    Time frame: 57 days

  2. To assess the PD effect of a single SC dose of HST101 on serum unbound (free) PCSK9 concentrations and serum LDL-C concentrations

    Serum free PCSK9 and LDL-C will be measured at baseline and various time points over 57 days

    Time frame: 57 days

  3. To assess the effect of a single SC dose of HST101 on blood lipids including TC, HDL-C, VLDL-C, and TG

    Serum TC,HDL-C,VLDL-C and TG(ISU:mmol/L)will be measured at baseline and various time points over 57 days to assess percent change from baseline over time

    Time frame: 57 days

  4. To assess the effect of a single SC dose of HST101 on serum ApoB, Apo A1 concentrations

    Serum Apo B(ISU:mg/dL) , Apo A1(ISU:mg/dL) concentrations will be measured at baseline and various time points over 57 days to assess percent change from baseline over time

    Time frame: 57 days

  5. To assess the effect of a single SC dose of HST101 on serum Lp(a) concentrations

    Serum Lp (a)(ISU: nmol/L) concentrations will be measured at baseline and various time points over 57 days to assess percent change from baseline over time

    Time frame: 57 days

  6. To assess the PK-PD relationship following a single SC dose of HST101

    The PK-PD relationship will be measured over 57 days

    Time frame: 57 days

  7. To assess immunogenicity (incidence, titer, and duration of ADAs/NAbs) following a single SC dose of HST101

    Measurement of ADAs/NAbs will be done at baseline and various intervals after HST101 administration

    Time frame: 57 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jan 2025, 3 months.

Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 16, 2024
StartActual
Sep 17, 2024
Primary completionActual
Jan 8, 2025
CompletionEst.
Mar 31, 2025
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06504043
Lead sponsor
Hasten Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
Sep 17, 2024
Primary completion
Jan 8, 2025
Completion
Mar 31, 2025 (estimated)
Last update
Mar 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lerodalcibep

Start the discussion